vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to Sell at Wall Street Zen

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday, Wall Street Zen reports.

A number of other equities analysts have also weighed in on the company. Zacks Research raised vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, September 7th. HC Wainwright decreased their target price on vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. BTIG Research reissued a "buy" rating and issued a $57.00 price target on shares of vTv Therapeutics in a report on Wednesday, October 14th. Lifesci Capital upgraded vTv Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of vTv Therapeutics in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.83.

vTv Therapeutics Trading Down 4.8%

vTv Therapeutics stock traded down $1.00 during mid-day trading on Friday, hitting $19.69. The stock had a trading volume of 17,404 shares, compared to its average volume of 21,876. vTv Therapeutics has a one year low of $19.04 and a one year high of $44.00. The firm has a market capitalization of $77.58 million, a P/E ratio of -21.40 and a beta of 0.28. The firm's 50 day moving average is $28.04 and its 200 day moving average is $32.91.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.94) EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $0.15. As a group, equities research analysts forecast that vTv Therapeutics will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. boosted its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) by 114.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,360 shares of the biotechnology company's stock after buying an additional 2,860 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in vTv Therapeutics were worth $161,000 as of its most recent SEC filing. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics is a U.S. clinical-stage biopharmaceutical company that discovers and develops small-molecule medicines for serious diseases. Its research has focused on metabolic conditions and other areas of significant medical need. The company's candidates have included cadisegliatin, formerly known as TTP399, an oral glucokinase activator studied as an addition to insulin therapy for people with type 1 diabetes, and azeliragon, an investigational compound studied for Alzheimer's disease. These are development-stage products, not established commercial medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.